Comparative efficiency of 13valent conjugate vaccine and 23valent polysaccharide vaccine in asthma patients

Abstract

Comparative data on clinical efficacy of pneumococcal vaccination with 13valent conjugate vaccine (PCV13) or 23valent polysaccharide vaccine (PPV23) in asthma patients have been reported in the article.

Aim. The was to evaluate clinical efficacy of PCV13 and PPV23 in patients with
asthma.

Methods. Clinical efficacy of vaccination was evaluated using exacerbation rate, need in antibiotics and hospitalizations. We estimated number of exacerbations, number of antibacterial courses and number of hospitalizations for asthma exacerbation in a year before and after vaccination.

Results. The study involved 58 asthma patients. Of them, 33 patients received a single dose of PCV13 intramuscularly and 25 patients received a single dose of PPV23 intramuscularly. Baseline characteristics were similar in both groups. In a year after the vaccination, number of exacerbation and hospitalizations due to asthma and need in antibiotics significantly reduced.

Conclusion. Vaccination of asthma patients with PCV13 or PPV23 vaccines was highly efficient with the benefit of PCV13. Further studies of microbiological, immunological and other effects of "Prevenar13" and "Pneumo23" in patients with asthma are needed.